Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

The Economic Costs of Alcohol and Drug Abuse in the United States - 1992

Table 4.20

Treatment Costs per Acute Hepatitis C Virus Case

Disease Stages/Conditions Probability of Stage
(%)
Number of Cases in 1992 Cost per Case in 1992
(dollars)
Total HCV Treatment Expenditures
(millions of dollars)
Total IVDU-Related HCV Expenditures
(millions of dollars)
Acute Disease Only
Subclinical 65.7 111,690 $6 $0.7 $0.3
Clinical, nonfulminant 34.0 57,800 $703 $40.6 $14.6
Fulminant 0.3 510 $12,124 $6.2 $2.2
Subtotal, Acute 100.0 170,000 NA $47.5 $17.1
Chronic Disease
Chronic carrier state 24.9 14,420 $950 $13.7 $4.9
Chronic persistent state 12.5 7,239 $1,618 $11.7 $4.2
Chronic active hepatitis 16.3 9,440 $67,486 $637.1 $229.3
Primary hepatic cancer 8.1 4,691 $103,148 $483.9 $174.2
Subtotal, Chronic ˜50 35,790 NA $1,146.3 $412.7
Total, All Conditions $1,193.8 $429.8
Source: Bloom et al. (1993).
Notes: Components may not sum to totals because of rounding. Intravenous drug use is estimated to cause 36 percent of hepatitis C (HCV) cases. Total probability of chronic disease stage (50 percent) is less than the sum of specific categories because more than one category of chronic stage is possible with any given case.


[Home Page][Economic Costs Index][Use the Back Button on Your Browser to Return to the Previous Page]

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal